- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.07. | Launching into an AI-powered future: a prescription for success | ||
| 06.07. | Klick Health acquires Oxford PharmaGenesis | ||
| 06.07. | ASCO 2026: the art of translation | ||
| 03.07. | Communiqué Awards 2026: Healthcare Communiquétor Neil Flash | ||
| 03.07. | Communiqué Awards 2026: celebrating excellence in healthcare communications | ||
| 02.07. | Sanofi announces phase 3 study data for infantile-onset Pompe disease | ||
| 02.07. | The outcomes economy: where next for pharma? | ||
| 01.07. | Zymeworks to acquire Theravance Biopharma in deal worth $929m | ||
| 01.07. | Achieving launch excellence through cross-functional collaboration | ||
| 30.06. | Roche's Enspryng given FDA Priority Review as thyroid eye disease treatment | ||
| 30.06. | Steering generative AI into the pharma fast lane | ||
| 29.06. | Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim | ||
| 26.06. | Pfizer announces phase 3 results for potential non-small cell lung cancer treatment | ||
| 26.06. | MRM Health appoints Hans-Jürgen Wörle as Independent Director | ||
| 25.06. | MRM Health appoints Michel Detheux as Chairman of the Board | ||
| 25.06. | Gilead's Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer | ||
| 24.06. | Sanofi's Cenrifki approved in Europe for secondary progressive MS without relapses | ||
| 24.06. | Lundbeck appoints Tarek Samad as EVP, Head of Research & Development | ||
| 23.06. | AbbVie to acquire Apogee Therapeutics in $10.9bn deal | ||
| 23.06. | Biogen to acquire RayThera in $1bn deal | ||
| 22.06. | Regeneron's New Drug Application for cemdisiran accepted for review by FDA and EMA | ||
| 22.06. | Sanofi appoints Paulo Fontoura as Global Head of R&D | ||
| 18.06. | Sanofi's Sarclisa approved by MHRA as UK's first anti-cancer treatment given via on-body injector | ||
| 18.06. | Pfizer appoints Cecile Guegan as Interim CFO | ||
| 17.06. | Takeda's new study data for oveporexton shows improvements in narcolepsy type 1 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.